Form 4: Relmada Therapeutics CFO Maged Shenouda Increases Stake in Company

Maged Shenouda, CFO of Relmada Therapeutics, recently acquired a significant number of common stock shares through open market purchases.

Summary

• On September 9, 2024, Maged Shenouda, the Chief Financial Officer of Relmada Therapeutics, purchased 8,194 shares of common stock at a weighted average price of $2.55.
• The purchase prices for these shares ranged from $2.49 to $2.60 per share.
• On September 10, 2024, Shenouda acquired an additional 21,118 shares at a weighted average price of $2.73, with prices ranging from $2.70 to $2.75 per share.
• On September 11, 2024, Shenouda continued purchasing, acquiring 24,120 shares at a weighted average price of $2.95, with prices ranging from $2.79 to $3.05 per share.
• Following these transactions, Shenouda directly owns 88,335 shares of Relmada Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CFO's significant stock purchases, indicating confidence in the company's prospects. However, it's crucial to consider the broader context before making investment decisions.

Positives

• The CFO's open market purchases may signal confidence in the company's future prospects.
• Increased insider ownership can align management's interests with those of shareholders.

Industry Context

Insider buying is often seen as a positive sign, suggesting that a company's management believes the stock is undervalued. However, it's important to consider the overall context of the company's performance and industry trends.

Stakeholder Impact

• Shareholders may view the CFO's stock purchases as a positive signal.
• The increased insider ownership could potentially boost investor confidence.

Key Dates

Keywords

Relmada Therapeutics, RLMD, Maged Shenouda, CFO, Insider Trading, Stock Purchase, Form 4, Beneficial Ownership